India Pharma Outlook Team | Thursday, 28 May 2026
India has taken a significant step in addressing the growing threat of antimicrobial resistance, with the national drug regulator granting approval to Wockhardt’s novel antibiotic Zaynich (Zidebactam/Cefepime).
The therapy has been cleared for marketing and import to treat complicated urinary tract infections (cUTI), including severe kidney infections (pyelonephritis) and cases involving Gram-negative bloodstream infections in adult patients.
The approval marks a major milestone for India’s pharmaceutical innovation landscape, as Zaynich is an indigenously discovered and developed, first-in-class antibiotic designed to tackle some of the most challenging drug-resistant infections.
Antimicrobial resistance (AMR) has emerged as one of the most pressing public health challenges globally, and India remains one of the most affected regions due to high antibiotic usage and rising resistance levels.
A key concern has been the increasing prevalence of carbapenem-resistant Gram-negative bacteria, which are difficult to treat and often leave clinicians with limited and toxic treatment options such as colistin.
Zaynich offers a potential breakthrough in this space. Clinical data from the Phase 3 ENHANCE-1 trial demonstrated that the drug not only met expectations but outperformed the widely used antibiotic meropenem. The study showed:
The results were even more striking in high-risk patients with bloodstream infections, where response rates reached 89% vs 44% for the comparator drug.
Zaynich’s strength lies in its dual mechanism of action, combining cefepime with zidebactam, which targets multiple bacterial pathways simultaneously. This makes it particularly effective against extensively drug-resistant (XDR) pathogens, including those driven by metallo-β-lactamase (MBL) enzymes—one of the toughest resistance mechanisms seen in India.
Earlier clinical studies and real-world compassionate use cases across countries such as India, the United States, and France have also shown strong efficacy in severe infections, especially where no effective alternatives were available.
Importantly, the drug has shown potential across a wide range of serious conditions beyond UTIs, including:
This broad applicability positions Zaynich as a critical addition to hospital-based infection management, particularly in intensive care settings.
Zaynich’s approval in India also aligns with its growing global recognition. The drug has received Priority Review, Fast Track, and Qualified Infectious Disease Product (QIDP) designations from the US FDA, highlighting its importance in addressing unmet medical needs.
Regulatory filings are already under review in both US and European Union, indicating Wockhardt’s ambition to position the drug as a global solution to antimicrobial resistance.
For India, this development signals a broader shift—from being a major supplier of generics to becoming a source of innovative, research-driven therapies. Wockhardt’s pipeline of six novel antibiotics further reinforces this transition, especially in the anti-infective space.
The approval of Zaynich is not just another drug launch—it reflects a strategic breakthrough in the fight against drug-resistant infections. For patients and clinicians, it brings a much-needed, more effective treatment option. For India’s pharma sector, it underscores the country’s growing capability to develop globally relevant, next-generation therapies at a time when the world urgently needs them.
.jpg)
.jpg)
